BioWorld

Nov. 9, 2005

View Archived Issues

Portola Series B Gets $46M For Anti-Thrombosis Work

Read More

With Lucentis BLA In Works, Genentech Reports AMD Data

Read More

Cellegy Stops Ghana HIV Trial; Broader Plans Moving Ahead

Read More

Other News To Note

Read More

Theravance Gets Telavancin Partner In Deal Worth $221M

With two Phase III programs ongoing for telavancin, Theravance Inc. found the antibiotic a global partner in Astellas Pharma Inc. through a deal worth up to $221 million. (BioWorld Today) Read More